magnolol has been researched along with Malignant Melanoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abu Eid, M; Bennett, B; Boyle, KA; Cheng, G; Dwinell, MB; Hardy, M; Kalyanaraman, B; Kresty, LA; McAllister, D; Weh, K; Zielonka, J; Zielonka, M | 1 |
| Ahmed, F; Chinna Chowdary, BR; Emran, AA; Haass, NK; Hammerlindl, H; Huefner, A; Schaider, H; Schuehly, W | 1 |
2 other study(ies) available for magnolol and Malignant Melanoma
| Article | Year |
|---|---|
Mitochondria-targeted magnolol inhibits OXPHOS, proliferation, and tumor growth via modulation of energetics and autophagy in melanoma cells.
Topics: Animals; Autophagy; Biphenyl Compounds; Cell Line, Tumor; Cytoprotection; Humans; Lignans; Melanoma; Mice; Mice, Nude; Mitophagy; Nitric Oxide Synthase; Oxidative Phosphorylation | 2020 |
Magnolol induces cell death through PI3K/Akt-mediated epigenetic modifications boosting treatment of BRAF- and NRAS-mutant melanoma.
Topics: Apoptosis; Biphenyl Compounds; Cell Death; Cell Line, Tumor; Epigenesis, Genetic; G1 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; GTP Phosphohydrolases; Humans; Lignans; Melanoma; Membrane Proteins; Models, Biological; Mutation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Signal Transduction | 2019 |